Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study.
Chemotherapy
Non-squamous cell carcinoma
Recurrence
Stage IVB
Uterine cervical cancer
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
11
08
2020
accepted:
20
03
2021
pubmed:
8
4
2021
medline:
23
6
2021
entrez:
7
4
2021
Statut:
ppublish
Résumé
This phase II study evaluated the efficacy and safety of docetaxel/carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix. A total of 50 patients with International Federation of Gynecology and Obstetrics stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix were enrolled and administered docetaxel at a dose of 60 mg/m The response rate was 47.9% with 5 patients achieving complete response, 18 partial response, 14 stable disease, and 6 progressive disease. The disease control rate was 77.1%. With a median follow-up duration of 368 days, the median progression-free survival and overall survival were 6.1 months (95% CI 5.5-8.6) and 15.8 months (95% CI 18.2-28.3), respectively. The most frequent grade 3 and grade 4 hematological toxicity was neutropenia, with 38 patients (81%) having grade 4 and 4 (9%) having grade 3 neutropenia. The non-hematological toxicities were mainly grade 1 or 2 in severity. Docetaxel/carboplatin chemotherapy was effective, with a higher disease control rate and well-tolerated chemotherapeutic regimen for patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix.
Sections du résumé
BACKGROUND
BACKGROUND
This phase II study evaluated the efficacy and safety of docetaxel/carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix.
METHODS
METHODS
A total of 50 patients with International Federation of Gynecology and Obstetrics stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix were enrolled and administered docetaxel at a dose of 60 mg/m
RESULTS
RESULTS
The response rate was 47.9% with 5 patients achieving complete response, 18 partial response, 14 stable disease, and 6 progressive disease. The disease control rate was 77.1%. With a median follow-up duration of 368 days, the median progression-free survival and overall survival were 6.1 months (95% CI 5.5-8.6) and 15.8 months (95% CI 18.2-28.3), respectively. The most frequent grade 3 and grade 4 hematological toxicity was neutropenia, with 38 patients (81%) having grade 4 and 4 (9%) having grade 3 neutropenia. The non-hematological toxicities were mainly grade 1 or 2 in severity.
CONCLUSION
CONCLUSIONS
Docetaxel/carboplatin chemotherapy was effective, with a higher disease control rate and well-tolerated chemotherapeutic regimen for patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix.
Identifiants
pubmed: 33826028
doi: 10.1007/s10147-021-01903-1
pii: 10.1007/s10147-021-01903-1
doi:
Substances chimiques
Docetaxel
15H5577CQD
Carboplatin
BG3F62OND5
Types de publication
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1314-1321Références
Arbyn M, Weiderpass E, Bruni L et al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8:e191–e203
doi: 10.1016/S2214-109X(19)30482-6
Yaegashi N (2020) Gynecologic cancer committee report in 2018. Acta Obstet Gynaecol Jpn 72:800–856
Smith HO, Tiffany MF, Qualls CR et al (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol 8:97–105
doi: 10.1006/gyno.2000.5826
Park JY, Kim DY, Kim JH et al (2010) Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of the uterine cervix. Br J Cancer 102:1692–1698
doi: 10.1038/sj.bjc.6605705
Galic V, Herzog TJ, Lewin SN et al (2012) Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 125:287–291
doi: 10.1016/j.ygyno.2012.01.012
Ojesina AI, Lichtenstein L, Freeman SS et al (2014) Landscape of genomic alterations in cervical carcinomas. Nature 506:371–375
doi: 10.1038/nature12881
Wright AA, Howitt BE, Myers AP et al (2013) Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776–3783
doi: 10.1002/cncr.28288
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Cervical Cancer version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/cervical_blocks.pdf . Accessed July 2020
Moore DH, Blessing JA, McQuellon RP et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119
doi: 10.1200/JCO.2004.04.170
Long HJ 3rd, Bundy BN, Grendys EC Jr et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4625–4633
doi: 10.1200/JCO.2005.10.021
Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655
doi: 10.1200/JCO.2009.21.8909
Tewari KS, Sill MW, Penson RT et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654–1663
doi: 10.1016/S0140-6736(17)31607-0
Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129–2135
doi: 10.1200/JCO.2014.58.4391
Takekida S, Fujiwara K, Nagao S et al (2010) Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. Int J Gynecol Cancer 20:1563–1568
pubmed: 21370599
Shimada M, Nagao S, Fujiwara K et al (2016) Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. Int J Clin Oncol 21:1128–1135
doi: 10.1007/s10147-016-1010-0
Sato S, Shimada M, Ohta T et al (2016) Feasibility study of adjuvant chemotherapy using taxane plus carboplatin for high-risk patients with uterine cervical non-squamous cell carcinoma after radical hysterectomy. Int J Gynecol Cancer 26:561–567
doi: 10.1097/IGC.0000000000000650
Rose PG, Tian C, Bookman MA (2010) Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol 117:324–329
doi: 10.1016/j.ygyno.2010.01.040
Lara PN, Redman MW, Kelly K et al (2008) Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 26:463–467
doi: 10.1200/JCO.2007.13.0344
Katsumata N, Hirai Y, Kamiura S et al (2011) Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer. Ann Oncol 22:1353–1357
doi: 10.1093/annonc/mdq602
Aoki Y, Ochiai K, Lim S et al (2018) Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. Br J Cancer 119:530–537
doi: 10.1038/s41416-018-0206-7
Takatori E, Shoji T, Suga Y et al (2014) A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcinoma of the uterine cervix. Int J Clin Oncol 19:336–340
doi: 10.1007/s10147-013-0539-4
Tewari KS, Sill MW, Long HJ III et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743
doi: 10.1056/NEJMoa1309748
Machida H, Matsuo K, Matsuzaki S et al (2020) Proposal two-tier system in grouping adenocarcinoma of uterine cervix. Cancers (Basel) 12:1251
doi: 10.3390/cancers12051251
Kojima A, Shimada M, Mikami Y et al (2018) Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the Sankai Gynecology Study Group. Int J Gynecol Cancer 28:99–106
doi: 10.1097/IGC.0000000000001145
Kojima A, Mikami Y, Sudo T et al (2007) Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol 31:664–672
doi: 10.1097/01.pas.0000213434.91868.b0
Kusanagi Y, Kojima A, Mikami Y et al (2010) Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Surg Pathol 177:2169–2175
doi: 10.2353/ajpath.2010.100323
Karamurzin YS, Kiyokawa T, Parkash V et al (2015) Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol 39:1449–1457
doi: 10.1097/PAS.0000000000000532